Milestone Pharmaceuticals (NASDAQ:MIST) Stock Rating Upgraded by Wall Street Zen

Milestone Pharmaceuticals (NASDAQ:MIST) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday.

Several other brokerages also recently issued reports on MIST. Weiss Ratings reiterated a “sell (d-)” rating on shares of Milestone Pharmaceuticals in a report on Monday, December 29th. Zacks Research downgraded Milestone Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, February 24th. HC Wainwright restated a “buy” rating and set a $8.00 price objective on shares of Milestone Pharmaceuticals in a research report on Tuesday, January 6th. TD Cowen raised Milestone Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Monday, December 15th. Finally, Wells Fargo & Company increased their target price on Milestone Pharmaceuticals from $4.00 to $8.00 and gave the company an “overweight” rating in a research report on Tuesday, December 16th. Three investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $8.00.

Milestone Pharmaceuticals Stock Performance

Shares of Milestone Pharmaceuticals stock opened at $1.04 on Friday. The firm has a market capitalization of $122.38 million, a PE ratio of -1.32 and a beta of 0.48. The company has a current ratio of 8.01, a quick ratio of 7.96 and a debt-to-equity ratio of 1.37. The firm’s 50 day moving average is $1.72 and its 200 day moving average is $1.97. Milestone Pharmaceuticals has a 1 year low of $0.63 and a 1 year high of $3.06.

Milestone Pharmaceuticals (NASDAQ:MIST) last issued its quarterly earnings data on Friday, March 20th. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.02. The company had revenue of $1.44 million during the quarter, compared to the consensus estimate of $37.52 million. Equities research analysts forecast that Milestone Pharmaceuticals will post -0.62 earnings per share for the current fiscal year.

Insider Activity

In other news, CEO Joseph Oliveto sold 43,000 shares of Milestone Pharmaceuticals stock in a transaction on Thursday, January 8th. The shares were sold at an average price of $2.25, for a total transaction of $96,750.00. Following the transaction, the chief executive officer owned 303,721 shares in the company, valued at approximately $683,372.25. The trade was a 12.40% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold a total of 113,693 shares of company stock worth $233,347 over the last ninety days. 19.50% of the stock is currently owned by company insiders.

Institutional Trading of Milestone Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of MIST. Sapient Capital LLC bought a new position in Milestone Pharmaceuticals during the 3rd quarter worth $25,000. Strategic Family Wealth Counselors L.L.C. bought a new stake in shares of Milestone Pharmaceuticals in the 4th quarter valued at about $25,000. Eaton Financial Holdings Company LLC acquired a new stake in shares of Milestone Pharmaceuticals in the fourth quarter valued at about $26,000. Bank of America Corp DE raised its position in shares of Milestone Pharmaceuticals by 200,550.0% during the third quarter. Bank of America Corp DE now owns 16,052 shares of the company’s stock worth $32,000 after acquiring an additional 16,044 shares during the last quarter. Finally, Stephenson & Company Inc. bought a new position in shares of Milestone Pharmaceuticals during the third quarter worth about $40,000. 86.18% of the stock is currently owned by institutional investors and hedge funds.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.